Spasentan/Sparsentan is a drug from which country?

Sparsentan is a drug discovered and developed by Pharmacopeia, Inc., originally named PS433540. The drug has a relatively long development process and has undergone multiple clinical trials and evaluations. In 2012, Travere Therapeutics took over and further promoted the development of sparsentan. Travere Therapeutics is a biopharmaceutical company focused on the treatment of kidney diseases, headquartered in the United States, committed to improving the quality of life of patients through innovative medicines.

Sparsentan is a dual endothelin and angiotensin receptor antagonist. This special drug mechanism gives it unique advantages in the treatment of conditions related to kidney disease. In the treatment of kidney disease, controlling proteinuria is an important therapeutic goal because high levels of proteinuria often portend worsening kidney function. Sparsentan's mechanism of action effectively reduces proteinuria in patients, particularly in adults with primary IgA nephropathy (IgAN) who are at risk for rapid disease progression and whose urine protein/creatinine ratio (UPCR) exceeds 1.5 g/g.

After verification in clinical trials, sparsentan received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2021 to bring this new therapy to the market more quickly. This move not only marks an important breakthrough in the history of drug research and development for sparsentan, but also brings new hope to the majority of IgAN patients. Sparsentan, marketed under the trade name Filspari, has become a new treatment option for IgAN on the market.

With the availability of sparsentane, patients can expect better results when treatingIgAN, especially those at risk for rapid disease progression. Clinical data show that patients using sparsentane have made significant progress in reducing proteinuria and improving renal function, which is undoubtedly an important improvement in patients' quality of life.

References:https://www.clinicaltrialsarena.com/news/travere-signs-120m-licencing-deal-with-renalys-for-sparsentan-in-asia/